TPR Coated Solid Dispersion Beads for Weakly Basic Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing oral pharmaceutical dosage forms that deliver weakly basic therapeutic agents with constant plasma concentrations is challenging due to varying pH conditions and solubility issues in the gastrointestinal tract, leading to unpredictable drug release profiles and potential side effects.
Innovation Solution
A pharmaceutical composition comprising a solid dispersion of a weakly basic active pharmaceutical ingredient combined with a solubility-enhancing polymer, coated with a timed pulsatile release (TPR) coating consisting of a water-insoluble and enteric polymer, which modulates the release rate to achieve a sustained release profile over 12-18 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If weakly basic drugs are administered orally, then the drug must pass through varying pH environments in the GI tract, but this causes unpredictable drug release profiles and potential side effects due to pH-dependent solubility changes
Solution Approach 1:
The patent changes the physical state of the weakly basic drug from crystalline to amorphous form within a solid dispersion matrix. This parameter change eliminates pH-dependent solubility variations by preventing crystallization and maintaining the drug in a highly soluble amorphous state, thereby ensuring predictable release profiles across varying GI pH conditions
Solution Approach 2:
The patent creates a composite material system consisting of the weakly basic drug dispersed within a polymer matrix. This composite structure provides controlled drug release by combining the drug with polymers that modulate dissolution behavior, ensuring consistent release rates regardless of external pH changes in the gastrointestinal tract
2Reliability
If high doses of weakly basic drugs are used to achieve therapeutic efficacy, then the drug may precipitate in the GI tract at pH>5, but this reduces bioavailability and therapeutic effectiveness
Solution Approach 1:
The patent changes the physical state of the drug from crystalline to amorphous form. This parameter change dramatically increases solubility and prevents precipitation at higher concentrations and pH levels, allowing high therapeutic doses to be administered without loss of bioavailability or therapeutic effectiveness
Solution Approach 2:
The patent introduces a polymer matrix as an intermediary that stabilizes the drug in solution. This intermediary prevents direct interaction between the drug and the GI tract environment, eliminating precipitation issues and maintaining stable drug composition throughout the digestive system
3Quantity of substance
If solid dispersions are used to enhance drug solubility, then immediate release occurs upon oral ingestion, but this prevents sustained release and constant plasma concentrations
Solution Approach 1:
The patent segments the solid dispersion into controlled-release units (beads or pellets) that are subsequently coated with an enteric coating. This segmentation allows the internal solid dispersion to provide high solubility while the external coating controls the release timing and duration, enabling both immediate dissolution and sustained release profiles
Solution Approach 2:
The patent performs preliminary action by pre-forming the solid dispersion within the bead matrix before applying the enteric coating. This preliminary creation of the soluble core ensures that when the coating dissolves in the intestine, the drug is already in a highly soluble amorphous state ready for controlled release, achieving both solubility enhancement and sustained release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TPR coating ensures a consistent and prolonged release of the active pharmaceutical ingredient, maintaining therapeutic plasma concentrations and minimizing side effects by delaying the release and providing a sustained therapeutic level over an extended period.
Implementation Method 1
a solid dispersion of a weakly basic active pharmaceutical ingredient and at least one solubility-enhancing polymer
Implementation Method 2
a timed pulsatile release (TPR) coating consisting of a water-insoluble and enteric polymer, which modulates the release rate
Data Source
AI summary
The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 μg/mL at pH 6.8.